

Supplementary Material

Synthesis, characterization, analgesic and anti-inflammatory activity of new pyrazole derivatives

Pullagura Priyadarsini,^a Vallabhaneni Madhavarao,^{a*} and Bodepudi Sudheer Chowdary^b


^a Dept. of Chemistry, Bapatla Engineering College, Bapatla, Acharya Nagarjuna University, Guntur (District), Andhra Pradesh-522 101, India

^b Dept. of Pharmacology, Bapatla College of Pharmacy, Jawaharlal Nehru Technical University-K, Bapatla, A.P., India


E-mail: vmrqpm@gmail.com

Table of Contents


Characterization (¹ H-NMR, ¹³ C-NMR & LC_MS) Data of Synthesized compounds	
PMR of compound 11, 14	S2
PMR of compound 15, 16	S3
PMR of compound 17, 19	S4
CMR of compound 11, 17	S5
CMR of compound 18	S6
MS of compound 11, 15	S7
MS of compound 17, 18	S8
Biological testing data: Tables S1 and S2	S9




3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-Nitrostyryl)-1-(2,4-dinitrophenyl) pyrazole




3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-(2,4-dinitrophenyl) pyrazole




3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-phenylpyrazole




3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)pyrazole




3-(4-Acetoxy-2-hydroxy phenyl)-5-(4-methoxystyryl)-1-(2, 4-dinitrophenyl) pyrazole




3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxystyryl)pyrazole




3-(4-Acetoxy-2-hydroxy phenyl)-5-(4-nitrostyryl)-1-(2, 4-dinitrophenyl) pyrazole




3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxystyryl)-1-(2,4-dinitrophenyl) pyrazole




3-(4-Acetoxy-2-hydroxy phenyl)-5-(4-methoxystyryl)-1-phenyl pyrazole




3-(4-Acetoxy-2-hydroxy phenyl)-5-(4-Nitrostyryl)-1-(2,4-dinitrophenyl) pyrazole



3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-chlorostyryl)-1-phenyl pyrazole



3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxystyryl)-1-(2,4-dinitrophenyl) pyrazole



3-(4-Acetoxy-2-hydroxyphenyl)-5-(4-methoxystyryl)-1-phenylpyrazole

Table S1. Analgesic activity by hot-plate method

Entry No.	Compound	Jumping response (mean \pm S.E.M) at		Activity after	
		30 min	60 min	30 min	60 min
1	Control	1.5 \pm 0.83	1.33 \pm 0.51	-	-
2	pentazocine	4.4 \pm 1.42	7.91 \pm 0.80	ns	***
3	11	4.1 \pm 0.75	11.5 \pm 1.87	ns	***
4	12	8.5 \pm 1.04	5.83 \pm 1.47	***	**
5	13	4.8 \pm 0.82	6.5 \pm 2.16	*	***
6	14	8.3 \pm 2.08	10.0 \pm 1.41	***	***
7	15	5.0 \pm 0.83	13.8 \pm 2.92	*	***
8	16	6.7 \pm 0.95	11.0 \pm 1.41	***	***
9	17	8.5 \pm 3.10	12.0 \pm 2.36	***	***
10	18	6.8 \pm 1.94	12.6 \pm 2.25	***	***
11	19	10 \pm 2.70	12.5 \pm 1.87	***	***

Note: *=P<0.05, **=P<0.01, ***=P<0.001 as compared to control, as per one way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test.

Table S2. Anti-inflammatory activity by carrageenan-induced method

S. No.	Compound	Paw edema (mean \pm S.E.M) at		% of inhibition after	
		30 min	60 min	30 min	60 min
1	Control	4.98 \pm 0.20	5.01 \pm 0.26	-	-
2	Indo-methacin	3.51 \pm 0.27	2.18 \pm 0.17	29.5	56.4
3	11	4.45 \pm 0.32	2.73 \pm 0.30	10.6	45.5
4	12	4.33 \pm 1.17	2.65 \pm 0.32	13.0	47.1
5	13	4.41 \pm 0.24	3.11 \pm 0.66	11.4	37.9
6	14	4.85 \pm 1.17	3.55 \pm 0.50	2.6	29.1
7	15	4.33 \pm 0.05	3.32 \pm 0.27	13.0	33.7
8	16	4.41 \pm 0.24	2.35 \pm 0.18	11.4	53.0
9	17	4.85 \pm 0.16	2.25 \pm 0.44	2.6	55.0
10	18	4.76 \pm 0.16	3.38 \pm 0.33	4.4	32.5
11	19	4.80 \pm 0.10	3.36 \pm 0.22	3.6	32.9